Cancer is a disease caused by genomic changes in the cells of our body. These changes, called mutations, can be harmful, beneficial, or have no effect. Harmful mutations can cause normal cells to grow and divide uncontrollably, leading to cancer.
Genomic profiling sheds light on the unique combination of mutations that makes each patient’s cancer unique. This information can be used to personalize treatment, so every patient gets the best treatment possible.
LiquidHALLMARK® provides Swift , Simple and Sensitive Genomic Profiling
LiquidHALLMARK is a genomic test that reveals crucial information about a tumor from just one blood draw. By detecting cancer-driving mutations in 80 different genes across 15 cancer types, LiquidHALLMARK can provide insight into the genomic changes that are driving each patient’s unique cancer.
Should you have any questions or need assistance, please contact our customer care team at [email protected].
LIQUIK-01 is our clinical trial comparing genomic profiles generated from liquid biopsy tests with conventional tissue testing in lung cancer.
With LIQUIK-01, patients can benefit from simple, non-invasive, and sensitive testing as a complement to tissue testing. This additional crucial information will allow the provider to decide on the best course of treatment for the patient.View Eligibility Criteria
We are currently recruiting patients with lung cancer from multiple sites in U.S. and Singapore. Speak to us to find out more.Contact Us